Metraipolis › archive › dc_da2185534033
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab deruxtecan efficacy in patients with HER2-positive gastric cancer — Europe PMC PMID:41925805
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41925805
- DOI
- 10.1007/s10120-[numero omesso]-9
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-03T12:15:48.803Z
- SHA-256 of the archived text
ab060a89d49306897e326768dab4992ca5700017e4c55629b2b8ed4ef0e62aee- Stable URL of this page
https://metraipolis.com/documento/dc_da2185534033
How to cite
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab deruxtecan efficacy in patients with HER2-positive gastric cancer — Europe PMC PMID:41925805 — Europe PMC (en), https://europepmc.org/article/MED/41925805 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_da2185534033 (Metraipolis archive dc_da2185534033, sha256 ab060a89d49306897e326768dab4992ca5700017e4c55629b2b8ed4ef0e62aee)
BibTeX
@misc{dcda2185534033,
title = {Clinical impact of intratumoral HER2 heterogeneity on trastuzumab deruxtecan efficacy in patients with HER2-positive gastric cancer — Europe PMC PMID:41925805},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41925805},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_da2185534033; sha256 ab060a89d49306897e326768dab4992ca5700017e4c55629b2b8ed4ef0e62aee},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41925805. Agents can read the archived copy with the MCP tool read_document.